Federated Hermes Inc. Sells 169,473 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Federated Hermes Inc. lowered its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 4.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,272,761 shares of the company's stock after selling 169,473 shares during the period. Federated Hermes Inc. owned approximately 6.83% of Amphastar Pharmaceuticals worth $202,420,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $28,000. Point72 Middle East FZE acquired a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter worth about $50,000. Ronald Blue Trust Inc. raised its holdings in shares of Amphastar Pharmaceuticals by 821.5% in the 3rd quarter. Ronald Blue Trust Inc. now owns 1,198 shares of the company's stock worth $55,000 after acquiring an additional 1,068 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 99.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,261 shares of the company's stock worth $58,000 after acquiring an additional 628 shares during the last quarter. Finally, Point72 Hong Kong Ltd acquired a new stake in shares of Amphastar Pharmaceuticals in the 1st quarter worth about $74,000. Institutional investors and hedge funds own 65.09% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on AMPH shares. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, April 10th. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price objective for the company. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, February 29th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $66.00.

Insider Activity

In other news, Director Floyd F. Petersen sold 500 shares of the stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now directly owns 80,333 shares of the company's stock, valued at approximately $4,265,682.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Michael A. Zasloff sold 12,500 shares of the firm's stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total value of $589,750.00. Following the completion of the transaction, the director now directly owns 21,326 shares of the company's stock, valued at approximately $1,006,160.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Floyd F. Petersen sold 500 shares of the firm's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total transaction of $26,550.00. Following the completion of the transaction, the director now directly owns 80,333 shares of the company's stock, valued at $4,265,682.30. The disclosure for this sale can be found here. Insiders sold 14,000 shares of company stock valued at $660,860 in the last three months. Company insiders own 28.40% of the company's stock.

Amphastar Pharmaceuticals Stock Performance

Shares of Amphastar Pharmaceuticals stock traded down $1.40 on Thursday, reaching $38.65. 329,460 shares of the company traded hands, compared to its average volume of 464,474. Amphastar Pharmaceuticals, Inc. has a 52 week low of $35.62 and a 52 week high of $67.66. The company has a 50 day moving average of $46.59 and a 200 day moving average of $51.23. The firm has a market capitalization of $1.89 billion, a PE ratio of 14.98, a PEG ratio of 0.98 and a beta of 0.84. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.17 and a quick ratio of 1.70.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share for the quarter, missing analysts' consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. Equities analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.42 earnings per share for the current year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.